# OnCo record sq3370 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sq3370/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sq3370" ;
  schema:name "SQ3370"@en ;
  schema:alternateName "SQL70 plus SQP33"@en, "SQL70"@en, "SQP33"@en, "doxorubicin protodrug SQP33"@en ;
  schema:description "SQ3370 is an experimental two-part treatment from Shasqi: a gel injected into a tumour, then an inactive form of the chemotherapy drug doxorubicin given into a vein, which the gel switches on. In its one trial, very high doses caused no dose-limiting side effects, but tumours responded no more often than with ordinary doxorubicin and the trial was stopped. It is not approved anywhere."@en ;
  schema:url <https://onco.cc/drugs/sq3370/> ;
  schema:dateModified "2026-11-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04106492>, <https://doi.org/10.1101/2025.06.02.25328445>, <https://doi.org/10.1158/1078-0432.CCR-24-2539>, <https://doi.org/10.1200/JCO.2024.42.16_suppl.11555>, <https://www.shasqi.com/our-platform>, <https://www.shasqi.com/pipeline>, <https://www.shasqi.com/post/shasqi-announces-click-chemistry-breakthrough-with-first-ever-human-application-in-launch-of-clinical-program>, <https://www.shasqi.com/post/shasqi-advances-sq3370-to-phase-2-in-solid-tumors> ;
  onco:status "phase-2" ;
  onco:tag "failure" ;
  onco:modality "Click-activated anthracycline prodrug in two parts: an activating biopolymer injected into the tumour and an intravenous doxorubicin prodrug" ;
  onco:related <https://onco.cc/drugs/doxorubicin/> ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/click-activated-prodrugs/> ;
  onco:companies <https://onco.cc/companies/shasqi/> ;
  onco:terms <https://onco.cc/terms/prodrug/>, <https://onco.cc/terms/anthracycline/>, <https://onco.cc/terms/rp2d/>, <https://onco.cc/terms/dose-limiting-toxicity/> ;
  onco:trials <https://onco.cc/trials/nct04106492/> ;
  onco:people <https://onco.cc/people/sant-chawla/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/>, <https://onco.cc/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/>, <https://onco.cc/key-papers/paper-srinivasan-sq3370-injected-and-non-injected-lesions-adv-ther-2021/>, <https://onco.cc/key-papers/paper-wu-click-activated-protodrugs-local-capture-chem-sci-2021/>, <https://onco.cc/key-papers/paper-mejia-oneto-local-hydrogel-systemic-prodrug-sarcoma-acs-cent-sci-2016/> .
